EGFRt-haNK(ImmunityBio)

N/A

Report date: 2022/09/06 18:03:23

Base Information

Drug NameEGFRt-haNK(ImmunityBio)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacementsEpidermal growth factor receptor erbB1 antagonists

TargetsEpidermal growth factor receptor erbB1

Therapy Area/IndicationsCarcinoma, Squamous Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNantkwest Inc Immunitybio Inc

China Registration ClassN/A

Develop Information

Active CompaniesNantkwest Inc

Inactive CompaniesN/A

Active IndicationsCarcinoma, Squamous Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A